Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.55 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 3/20 | 0.45 |
| ▸ | DRD3 | P35462 | 3/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | HRH2 | P25021 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4228461 | 0.85 | HRH3 (0.57) | HRH3MAOAMAOBDRD2DRD3 | |
| SCHEMBL4237104 | 0.80 | HRH3 (0.85) | HRH3MAOAMAOBHRH1CCR3 | |
| SCHEMBL4238046 | 0.78 | MAOA (0.47) | HRH3MAOAMAOB | |
| SCHEMBL4231975 | 0.78 | HRH3 (0.57) | HRH3MAOAMAOBDRD2DRD3 | |
| SCHEMBL4237496 | 0.77 | HRH3 (0.56) | HRH3MAOAMAOBDRD2DRD3 | |
| SCHEMBL4233991 | 0.77 | HRH3 (0.56) | HRH3MAOAMAOBDRD2DRD3 | |
| SCHEMBL4233735 | 0.77 | HRH3 (0.56) | HRH3MAOAMAOBDRD2DRD3 | |
| SCHEMBL4237668 | 0.76 | HRH3 (0.44) | HRH3MAOAMAOBHRH1NOS3 | |
| SCHEMBL4233907 | 0.74 | HRH3 (0.53) | HRH3MAOAMAOBDRD2DRD3 | |
| SCHEMBL4242600 | 0.73 | HRH3 (0.49) | HRH3HRH1CCR3HRH2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | HRH3 210/4885MAOA 219/4885MAOB 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.